Modified Virus Infects Tumors and Activates the Immune System with Mark Bertagnolli ViroMissile TRANSCRIPT
Download PDFFeb 25, 2026
Mark Bertagnolli, Chief Operating Officer at ViroMissile, has developed a modified vaccinia virus that can be delivered intravenously to seek out and destroy solid tumors throughout the body and is not dependent on a specific genetic driver of a cancer. The virus has been engineered to be resistant to the...
Feb 25, 2026
Mark Bertagnolli, Chief Operating Officer at ViroMissile, has developed a modified vaccinia virus that can be delivered intravenously to seek out and destroy solid tumors throughout the body and is not dependent on a specific genetic driver of a cancer. The virus has been engineered to be resistant to the...
DNA Immunotherapy Shows Durable Response in Advanced Melanoma with Phil L’Huillier Scancell TRANSCRIPT
Download PDFOct 30, 2025
Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care...
Oct 30, 2025
Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care...
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT
Download PDFSep 12, 2025
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier....